ClinicalTrials.gg
RecruitingNCT07646847Updated Oct 28, 2026

A Study of a Side Effects and Resource Navigation Program for People With Cancer

An interventional study of Immunotherapy CARE Program in Kidney Cancer, Bladder Cancer and Breast Cancer, sponsored by Memorial Sloan Kettering Cancer Center. Recruiting at 8 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-28.

Sponsored by Memorial Sloan Kettering Cancer Center · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Started Jun 2026; still recruiting 5 months later.
Updated Oct 28, 2026Eligibility revisedStart date movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 35 studies in Kidney Neoplasms by Memorial Sloan Kettering Cancer Center — 4 open to participants now, 9 under way, none of them phase 3. Kidney Neoplasms · Memorial Sloan Kettering Cancer Center.

Planned enrollment
4th of 21
200 · median 24
Started
2026
with 1 other
No phase
3 of 35
1 open now
Registered
34th of 35
by date

Among the 35 studies in Kidney Neoplasms by Memorial Sloan Kettering Cancer Center, this one is the 4th largest by planned enrollment of the 21 interventional ones that give a count, is one of 2 that started in 2026, is one of 3 with no phase, and was the 34th registered.

Kidney Neoplasms

969 studies on the registry are indexed under Kidney Neoplasms; 208 are open to participants now.

Browse Kidney Neoplasms studies →

Open to participants now

4 of the 35 studies in Kidney Neoplasms by Memorial Sloan Kettering Cancer Center are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 171 Kidney Neoplasms studies recruiting now, 131 (77%) set no upper age limit and 15 (9%) stop at 75 or younger; 20 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 35 studies in Kidney Neoplasms by Memorial Sloan Kettering Cancer Center, or all of them as a file.
02

Study summary

The purpose of this study is to find out if the navigation program helps participants manage immunotherapy treatment better than usual care. Investigators will also look at how the navigation program impacts participants' quality of life. Investigators will measure quality of life by having participants complete questionnaires.

03

Conditions studied

  • Kidney Cancer
  • Bladder Cancer
  • Breast Cancer
  • Lung Cancer

Keywords

  • Kidney Cancer
  • Bladder Cancer
  • Breast Cancer
  • Lung Cancer
  • Memorial Sloan Kettering Cancer Center
  • 25-338
04

Who can participate

The criteria were revised on the registry on Oct 28, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • Documentation of Disease

    o Patient must have confirmed kidney, bladder, breast, gastrointestinal or lung cancer (per EMR)

  • Prior Treatment

    o Within three weeks (+/- 3 weeks) of starting or PD(L)-1 immune checkpoint inhibitors as monotherapy or in combination with other therapies (per EMR)

  • Age ≥ 18 (per EMR)
  • Not Pregnant and Not Nursing (per self-report)
  • At least one essential need (e.g., food, transportation, housing), as determined by the ICCAN Essential Needs Screener (per self-report)
  • Screens positive on SDOH screening tool, referred by the clinical team through traditional screening tools for SDOH assistance orand demonstrates financial need per MSK guidelines (up to 500% of the federal poverty limit) (per EMR or self-report)
  • Lives in New York metro area, including Long Island, New Jersey, Connecticut, and Pennsylvania (per self-report)
  • Can speak English or Spanish (per self-report)
  • Has no serious life-threatening allergies to tape or adhesives (per EMR or self-report)
  • Has no significant psychiatric disturbance sufficient to preclude completion of the assessment measures, interview, or (i.e., acute psychiatric symptoms which require individual treatment) (per EMR, patient's care team, or study team)
  • Has no presence of cognitive impairment disorder (i.e., delirium or dementia) sufficient to preclude meaningful informed consent and/or data collection (per EMR, patient's care team, or study team)
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    I CARE Group

    Immunotherapy CARE Program

    Other: Immunotherapy CARE Program

  • No intervention
    U&C Group

    Enhanced Usual and Customary care and support (U\&C)

Interventions

  • OtherImmunotherapy CARE Program

    For participants assigned to the I CARE arm, CCNY staff will assist in monthly essential needs and side effects/symptom reporting navigation

    Also known as: I CARE

06

What researchers measure

Primary outcomes

  1. Immune Checkpoint Inhibitors/ICI continuation

    Participant ICI appointment and treatment adherence will be documented through chart abstraction (research staff EMR review) at 6 months

    Time frame: 6 months

07

Study locations

7 of 8 sites recruiting
  • Memorial Sloan Kettering Basking Ridge (All Protocol Activities)
    Basking Ridge, New Jersey 07920, United States
    Recruiting
    • Francesca Gany, MD, MS · Contact646-888-8054
  • Memorial Sloan Kettering Monmouth (All Protocol Activities)
    Middletown, New Jersey 07748, United States
    Recruiting
    • Francesca Gany, MD, MS · Contact646-888-8054
  • Memorial Sloan Kettering Bergen (All Protocol Activities)
    Montvale, New Jersey 07645, United States
    Recruiting
    • Francesca Gany, MD, MS · Contact646-888-8054
  • Memorial Sloan Kettering Suffolk- Commack (All Protocol Activities)
    Commack, New York 11725, United States
    Recruiting
    • Francesca Gany, MD, MS · Contact646-888-8054
  • Memorial Sloan Kettering Westchester (All Protocol Activities)
    Harrison, New York 10604, United States
    Recruiting
    • Francesca Gany, MD, MS · Contact646-888-8054
  • City College of New York (Data Collection AND Specimen Analysis)
    New York, New York 10031, United States
    Not yet recruiting
  • Memorial Sloan Kettering Cancer Center (All Protocol Activities)
    New York, New York 10065, United States
    Recruiting
    • Francesca Gany, MD, MS · Contact646-888-8054
  • Memorial Sloan Kettering Nassau (All protocol activities)
    Rockville Centre, New York 11553, United States
    Recruiting
    • Francesca Gany, MD, MS · Contact646-888-8054
08

References and documents

Individual participant data

Plan to share: Yes — Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made following one year after publication and for up to 36 months later. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for Jun 2029, 36 months after the start.

Of 90 non-industry interventional studies with no phase under Kidney Neoplasms, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 94. This study's planned 36 months is below that.

Counting every sponsor, half of 97 studies reached it within 42 months; a quarter within 21 and three quarters within 90.

Start moved once since we started tracking on Sep 25, 2026: Sep 2026 → Jun 2026, on Oct 20, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 9, 2026
First posted
Jun 15, 2026
StartActual
Jun 9, 2026was Sep 2026
Primary completionEst.
Jun 9, 2029
CompletionEst.
Jun 9, 2029
Last update
Oct 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Sep 14, 2026→Jun 9, 2026 (actual)
Oct 20, 2026
Eligibility
1 criterion edited, 2 added
What changed in the criteria
  • Editedo Patient must have pathologically confirmed kidney, bladder, breast, gastrointestinal or lung cancer (per EMR)
  • AddedScreens positive on SDOH screening tool, referred by the clinical team through traditional screening tools for SDOH assistance orand demonstrates financial need per MSK guidelines (up to 500% of the federal poverty limit) (per EMR or self-report)
  • AddedHas no serious life-threatening allergies to tape or adhesives (per EMR or self-report)
Oct 28, 2026
Show all 2 updates
  1. Oct 28, 2026
    Eligibility 1 criterion edited, 2 added
    What changed in the criteria
    • Editedo Patient must have pathologically confirmed kidney, bladder, breast, gastrointestinal or lung cancer (per EMR)
    • AddedScreens positive on SDOH screening tool, referred by the clinical team through traditional screening tools for SDOH assistance orand demonstrates financial need per MSK guidelines (up to 500% of the federal poverty limit) (per EMR or self-report)
    • AddedHas no serious life-threatening allergies to tape or adhesives (per EMR or self-report)
  2. Oct 20, 2026
    Start date Sep 14, 2026→Jun 9, 2026 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07646847
Responsible party
Sponsor
First posted
Jun 15, 2026
Start date
Jun 9, 2026
Primary completion
Jun 9, 2029 (estimated)
Completion
Jun 9, 2029 (estimated)
Last update
Oct 28, 2026

Study contacts

Francesca Gany, MD, MS
Contact
ganyf@mskcc.org
646-888-8054
Neil Shah, MBBS
Contact
ShahN6@mskcc.org
646-888-4239
Francesca Gany, MD, MS
principal investigator · Memorial Sloan Kettering Cancer Center

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion